Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 12/20 | 0.41 |
| ▸ | CTSG | P08311 | 1/20 | 0.36 |
| ▸ | HTRA1 | Q92743 | 5/20 | 0.34 |
| ▸ | DPP4 | P27487 | 3/20 | 0.32 |
| ▸ | DPP8 | Q6V1X1 | 2/20 | 0.32 |
| ▸ | DPP9 | Q86TI2 | 2/20 | 0.32 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.32 |
| ▸ | FAP | Q12884 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6742331 | 0.84 | DPP4 (0.45) | ELANECTSGHTRA1DPP4DPP8 | |
| SCHEMBL6740047 | 0.81 | ELANE (0.46) | ELANECTSGHTRA1 | |
| SCHEMBL31061570 | 0.77 | ELANE (0.62) | ELANECTSGDPP4DPP8DPP9 | |
| SCHEMBL6745333 | 0.76 | ELANE (0.65) | ELANECTSG | |
| SCHEMBL8428295 | 0.71 | ELANE (0.59) | ELANECTSGDPP4DPP8DPP9 | |
| SCHEMBL6743718 | 0.70 | ELANE (0.48) | ELANECTSG | |
| SCHEMBL6738003 | 0.68 | CMA1 (0.52) | ELANECTSG | |
| SCHEMBL7408175 | 0.67 | ELANE (0.51) | ELANECTSGDPP4DPP8DPP9 | |
| SCHEMBL7408179 | 0.67 | ELANE (0.51) | ELANECTSGDPP4DPP8DPP9 | |
| SCHEMBL22566026 | 0.65 | DPP4 (0.43) | ELANEDPP4DPP8DPP9DPP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6693072-B2 | Elastase inhibitors | AVENTIS PHARMACEUTICALS INC. | 2004-02-17 | — | — | US | disclosed |
| EP-0804465-B1 | NOVEL ELASTASE INHIBITORS | AVENTIS PHARMA INC (US) | 2003-08-06 | — | — | EP | disclosed |
| US-20030096759-A1 | Novel elastase inhibitors | AVENTISUB II INC. | 2003-05-22 | — | — | US | disclosed |
| EP-0804465-A1 | NOVEL ELASTASE INHIBITORS | HOECHST MARION ROUSSEL, INC. (US) | 1997-11-05 | — | — | EP | disclosed |
| WO-1995033763-A1 | NOVEL ELASTASE INHIBITORS | HOECHST MARION ROUSSEL, INC. (US) | 1995-12-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030096759-A1 | Novel elastase inhibitors | ELANE, SERPINB1, MMP8 | ELANE 1/4885CTSG 91/4885HTRA1 194/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.